Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CuraGen and TopoTarget initiate trial of anticancer drug
The trial is being sponsored by the National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for PXD101. The phase I portion of the study aims
The trial is being sponsored by the National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for PXD101. The phase I portion of the study aims
The Swiss drug maker has also declared its offer for the UK biopharmaceutical company unconditional in all respects. This will allow for the delisting of NeuTec’s shares and
The jury found that Merck had acted responsibly in informing the medical community about the benefits and risks of the osteoporosis drug that was voluntarily withdrawn from the
The resubmission of the new drug application (NDA) addresses deficiencies in the original application outlined by the FDA in a non-approvable letter in August 2002. The FDA has
On May 27, 2005, Abraxis entered into a license agreement with Taiho, a subsidiary of Otsuka Pharmaceutical, under which Abraxis granted Taiho the exclusive rights to market and
Epix said following Berlin-based Schering’s decision not to exercise its option it will retain full rights to the EP-2104R program. Schering is in the process of being acquired
The FDA notified the clinical stage biopharmaceutical company that it has satisfactorily addressed the majority of the issues raised in the March 29, 2006 clinical hold letter and
The researchers found that the two treatments for empyema (a build-up of pus) in the space surrounding the lungs were about as effective as each other, but concluded
LP-261, which is predicted to bind to tubulin in a novel way, was developed by Locus using its proprietary computational drug design capabilities. This drug candidate is distinguished
The FDA generally follows the recommendations of its advisory committees, although it is not obligated to do so. Nabi Biopharmaceuticals submitted its biologic license application (BLA) for Nabi-HB